Novel agents for anti-platelet therapy

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Ji, Xuebin ^a   Hou, Ming ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

agent; antagonist; anti platelet; therapy; thrombotic disease

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ATOPAXAR; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; EPTIFIBATIDE; PRASUGREL; TICLOPIDINE; TIROFIBAN; VORAPAXAR; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; BLEEDING; HUMAN; INTERMITTENT CLAUDICATION; PERIPHERAL ISCHEMIA; REVIEW; THROMBOSIS;

HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 80355125146     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-44     Document Type: Review

References (49)

1. Platelet aggregation inhibition with glycoprotein IIb - IIIa inhibitors. Proimos G, J Thromb Thrombolysis 2001 11 99 110 (Pubitemid 32691209)
2. Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention. Vergara-Jimenez J, Tricoci P, Vasc Health Risk Manag 2010 6 39 45
3. New antithrombotic drugs. Gross PL, Weitz JI, Clin Pharmacol Ther 2009 86 139 146
4. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess anti-platelet efficacy. Lippi G, Montagnana M, Danese E, Favaloro EJ, Franchini M, Biomark Med 2011 5 63 70
5. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. Winchester DE, Wen X, Brearley WD, Park KE, Anderson RD, Bavry AA, J Am Coll Cardiol 2011 57 1190 1199
6. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A metanalysis of phase III multicenter randomized trials. Chew DP, Bhatt DL, Sapp S, Topol EJ, Circulation 2001 103 201 206 (Pubitemid 32095403)
7. Cilostazol for prevention of secondary stroke (CSPS2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C, CSPS 2 group, Lancet Neurol 2010 9 959 968
8. Adding cilostazol to dual anti-platelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, Kwak CH, Park SW, Circ Cardiovasc Interv 2010 3 17 26
9. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Kim JY, Lee K, Shin M, Ahn M, Choe H, Yoo BS, Yoon J, Choe KH, Lee SH, Lancet Neurol 2008 7 494 499
10. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X, Fan D, Zeng J, Wong K, Lu C, Xiao J, Yao C, Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention cooperation investigators, Lancet Neurol 2008 7 494 499
11. Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. Lee JH, Cha JK, Lee SJ, Ha SW, Kwon SU, Eur J Neurol 2010 17 434 442
12. Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation. Cleanthis M, Bhattacharya V, Smout J, Ashour H, Stansby G, Eur J Vasc Endovasc Surg 2009 37 604 610
13. The P2 receptors in platelet function. Hechler B, Cattaneo M, Gachet C, Semin Thromb Hemost 2005 31 150 161 (Pubitemid 40605190)
14. Mode of action of P2Y(12) antagonists as inhibitors of platelet function. Iyú D, Glenn JR, White AE, Fox SC, van Giezen H, Nylander S, Heptinstall S, Thromb Haemost 2011 105 96 106
15. P2Y receptors in health and disease. Erlinge D, Adv Pharmacol 2011 61 417 439
16. State of the art of new P2Y12 antagonists. Cattaneo M, Podda GM, Intern Emerg Med 2010 5 385 391
17. Prasugrel versus clopidogrel in patients with acute coronary syndromes. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators, N Engl J Med 2007 357 2001 2015 (Pubitemid 350106708)
18. Prasugrel: a novel platelet ADP P2Y(12) receptor antagonist. Mousa SA, Jeske WP, Fareed J, Methods Mol Biol 2010 663 221 228
19. Update on the clinical development of cangrelor. Ueno M, Ferreiro JL, Angiolillo DJ, Expert Rev Cardiovasc Ther 2010 8 1069 1077
20. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies. Bliden KP, Tantry US, Storey RF, Jeong YH, Gesheff M, Wei C, Gurbel PA, Am Heart J 2011 162 160 165
21. Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L, on behalf of the PLATO Investigators, Circulation 2011 124 544 554
22. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L, Circulation 2010 122 1056 1067
23. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators, Freij A, Thorsén M, N Engl J Med 2009 361 1045 1057
24. Oral anti-platelet therapy for atherothrombotic disease: current evidence and new directions. White HD, Am Heart J 2011 161 450 461
25. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to anti-platelet therapy for atherothrombotic disease. Chintala M, Shimizu K, Ogawa M, Yamaguchi H, Doi M, Jensen P, J Pharmacol Sci 2008 108 433 438
26. SCH 530348: a novel oral thrombin receptor antagonist. Bonaca MP, Morrow DA, Future Cardiol 2009 5 435 442
27. Improving anti-platelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1. Hildemann SK, Bode C, Hamostaseologie 2009 29 349 355
28. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. Oestreich J, Curr Opin Investig Drugs 2009 10 988 996
29. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Kogushi M, Matsuoka T, Kawata T, Kuramochi H, Kawaguchi S, Murakami K, Hiyoshi H, Suzuki S, Kawahara T, Kajiwara A, Hishinuma I, Eur J Pharmacol 2011 657 131 137
30. Oral administration of the thrombin receptor antagonist E5555 (atopaxar) attenuates intimal thickening following balloon injury in rats. Kogushi M, Matsuoka T, Kuramochi H, Murakami K, Kawata T, Kimura A, Chiba K, Musha T, Suzuki S, Kawahara T, Kajiwara A, Hishinuma I, Eur J Pharmacol 2011 666 158 164
31. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, Bhatt DL, Thromb Haemost 2009 102 111 119
32. Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs. Vanhoorelbeke K, Ulrichts H, Schoolmeester A, Deckmyn H, Curr Drug Targets Cardiovasc Haematol Disord 2003 3 125 140 (Pubitemid 36621797)
33. Von Willebrand factor can support platelet aggregation via interaction with activated GPIIb-IIIa and GPIb. Naimushin YA, Mazurov AV, Platelets 2004 15 419 425 (Pubitemid 39518183)
34. Delineating the roles of the GPIIb/IIIa and GP-Ib-IX-V platelet receptors in mediating platelet adhesion to adsorbed fibrinogen and albumin. Sivaraman B, Latour RA, Biomaterials 2011 32 5365 5370
35. GPVI levels in platelets: relationship to platelet function at high shear. Best D, Senis YA, Jarvis GE, Eagleton HJ, Roberts DJ, Saito T, Jung SM, Moroi M, Harrison P, Green FR, Watson SP, Blood 2003 102 2811 2818 (Pubitemid 37248851)
36. Platelet-collagen interaction: is GPVI the central receptor? Nieswandt B, Watson SP, Blood 2003 102 449 461 (Pubitemid 36841960)
37. Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs. De Meyer SF, Vanhoorelbeke K, Ulrichts H, Staelens S, Feys HB, Salles I, Fontayne A, Deckmyn H, Cardiovasc Hematol Disord Drug Targets 2006 6 191 207 (Pubitemid 44377772)
38. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Fontayne A, Meiring M, Lamprecht S, Roodt J, Demarsin E, Barbeaux P, Deckmyn H, Thromb Haemost 2008 100 670 677
39. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Cauwenberghs N, Meiring M, Vauterin S, van Wyk V, Lamprecht S, Roodt JP, Novák L, Harsfalvi J, Deckmyn H, Kotzé HF, Arterioscler Thromb Vasc Biol 2000 20 1347 1353 (Pubitemid 30262938)
40. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. Diener JL, Daniel Lagassé HA, Duerschmied D, Merhi Y, Tanguay JF, Hutabarat R, Gilbert J, Wagner DD, Schaub R, Thromb Haemost 2009 7 1155 1162
41. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Firbas C, Siller-Matula JM, Jilma B, Expert Rev Cardiovasc Ther 2010 8 1689 1701
42. GPVI and alpha2beta1 play independent critical roles during platelet adhesion and aggregate for mation to collagen under flow. Sarratt KL, Chen H, Zutter MM, Santoro SA, Hammer DA, Kahn ML, Blood 2005 106 1268 1277 (Pubitemid 41129590)
43. Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation. Moog S, Mangin P, Lenain N, Strassel C, Ravanat C, Schuhler S, Freund M, Santer M, Kahn M, Nieswandt B, Gachet C, Cazenave JP, Lanza F, Blood 2001 98 1038 1046
44. The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces In Vivo thrombosis without bleeding risk in rats. Li H, Lockyer S, Concepcion A, Gong X, Takizawa H, Guertin M, Matsumoto Y, Kambayashi J, Tandon NN, Liu Y, Arterioscler Thromb Vasc Biol 2007 27 1199 1205 (Pubitemid 46641979)
45. Anti GPVI human antibodies neutralizing collagen induced platelet aggregation isolated from a combinatorial phage display library. Qian MD, Villeval JL, Xiong X, Jandrot-Perrus M, Nagashima K, Tonra J, McDonald K, Goodearl A, Gill D, Hum Antibodies 2002 11 97 105 (Pubitemid 35417408)
46. Identification of the primary collagen binding surface on human glycoprotein by site directed mutagenesis and by a blocking phage antibody. Smethurst PA, Joutsi-Korhonen L, O'Connor MN, Wilson E, Jennings NS, Garner SF, Zhang Y, Knight CG, Dafforn TR, Buckle A, IJsseldijk MJ, De Groot PG, Watkins NA, Farndale RW, Ouwehand WH, Blood 2004 103 903 911 (Pubitemid 38129549)
47. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy. Grüner S, Prostredna M, Aktas B, Moers A, Schulte V, Krieg T, Offermanns S, Eckes B, Nieswandt B, Circulation 2004 110 2946 2951 (Pubitemid 39473622)
48. The potential benefits of low-molecular-weight heparins in cancer patients. Robert F, J Hematol Oncol 2010 3 3
49. The clinical potential of microRNAs. Budhu A, Ji J, Wang XW, J Hematol Oncol 2010 3 37